Psychedelic experiences can produce intense changes in perception, emotion, the sense of self and the relationship with memories. Neuroscience is studying what happens in the brain during and after these states, but it does not yet have a complete explanation.
The brain does not simply “switch off”
Early magnetic-resonance studies reported changes in blood flow and communication between brain networks under psilocybin. Some findings showed reduced coherence within usually stable networks, including the so-called default mode network.
This does not mean that a particular region stops working or that there is a single “ego centre”. Imaging provides indirect measurements and group averages from relatively small samples; it cannot read an individual's experience.
More communication between networks, with caveats
Later research has described less separation and greater global communication between networks in certain clinical contexts. These changes have been associated with more flexible brain patterns.
An association does not prove that one change causes another. Nor can it guarantee benefit for a particular person. Substance, dose, setting, psychological support and participant characteristics all influence results.
Experience and context matter
In clinical trials, the substance is not studied in isolation: there is usually prior screening, preparation, support during the session and follow-up. Their results therefore cannot be transferred directly to use without assessment or support.
Subjective intensity is not automatically equivalent to effectiveness. A difficult experience may require care and integration, while a positive experience does not guarantee lasting change.
What clinical trials show
Some psilocybin trials with psychological support have reported reductions in depressive symptoms in selected groups. Other results have been more modest or have not shown significant superiority on the primary outcome over a comparator treatment.
Adverse effects including headache, nausea, dizziness, anxiety and transient confusion have also been recorded. Research continues to define who might benefit, with what support and under what safety conditions.
What we still do not know
There is no brain biomarker that reliably predicts an individual's response. Questions remain about long-term effects, individual differences, rare risks and the specific contribution of preparation and integration.
Neuroscience can deepen understanding, but it cannot replace clinical assessment, ethics, consent or human care.
Reading the evidence responsibly
- Distinguish a preliminary finding from an established conclusion.
- Do not confuse brain correlation with cause or cure.
- Consider sample size and how participants were selected.
- Remember that trials include structured support.
- Acknowledge adverse effects, uncertainty and limits of knowledge.
Research cited
- Carhart-Harris et al., PNAS (2012): neuroimaging during the psilocybin state
- Daws et al., Nature Medicine (2022): network integration after psilocybin therapy
- Carhart-Harris et al., NEJM (2021): psilocybin versus escitalopram trial
- Goodwin et al., NEJM (2022): single-dose trial in treatment-resistant depression
Understanding the evidence also means respecting its limits. Before any intense process, the priority should be an honest individual assessment and an appropriate safety framework.
Related articles
Returning to everyday life: caring for integration after an intense experience
Simple care for the first hours and days, sustainable next steps and signs that indicate when to seek help.
Read articleSafetyAncestral medicine retreat safety: what to consider before participating
A practical guide to assessing care, consent, the support team and post-experience follow-up.
Read article